The FDA has approved the Genio® system for treating patients with moderate to severe obstructive sleep apnea (OSA) with an ...

After years of being cleared on the European market, Nyxoah’s neuromodulation therapy for obstructive sleep apnea has now ...

The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.

Nyxoah is in the midst of a lawsuit brought on by Inspire Medical Systems alleging infringement of several patents related to its recently-cleared offering, Genio.

Nyxoah SA may now help make dreams come true here in the U.S. with its FDA approval for the Genio system for the treatment of ...

Nyxoah SA (NASDAQ:NYXH) saw its stock rise 9.4% after the FDA granted approval for its Genio system designed to treat ...

Investing.com -- Nyxoah SA (BR:NYXH) (NASDAQ: NYXH) stock jumped 9.4% following FDA approval of its Genio system for treating moderate to severe obstructive sleep apnea (OSA).

The system is compatible with 1.5T and 3T magnetic resonance imaging scans and eliminates the need for an implanted battery.

Preliminary, Unaudited Second Quarter 2025 Financial Results and Business Updates Announced on August 8, 2025, that the U.S.

DermaRite Industries is recalling certain lots of its over-the-counter soaps, antiseptics, and analgesics due to ...

Nyxoah announced today that it received FDA approval for its Genio neuromodulation device for treating sleep apnea.